🇺🇸

US SEC Filing Intelligence

· daily

Global High-Priority Regulatory Events — June 22, 2026

The 50 filings for June 22, 2026, reveal a market dominated by corporate actions (M&A, buybacks, delistings) and financial distress signals, with a notable concentration of insolvency proceedings and promoter stake sales. Key period-over-period trends show a sharp divergence: Kalpataru Projects International reported robust 22% revenue and 82% profit growth, while Ishan Dyes and Chemicals swung to a deep loss on a 28% revenue decline. Insider activity is mixed, with a significant promoter sale at Adishakti Loha and Ispat (3.26% stake reduction) contrasting with a near-doubling of a promoter's stake at Jaro Institute of Technology. Capital allocation is active, highlighted by Bajaj Auto's massive ₹5,632.8 crore buyback and Hindustan Zinc's full release of a 50.1% share encumbrance. The most critical developments include the voluntary delisting of Tulive Developers, deferred revival plans at Amalgamated Electricity Co., and ongoing CIRP meetings for Videocon and Value Industries. Key themes include a wave of promoter restructuring via inter-se transfers, a focus on shareholder returns through buybacks and dividends, and persistent stress in the textile and chemicals sectors.

50 high priority 50 total filings
· daily

US Executive Officer Management Changes SEC — June 22, 2026

This digest covers 50 regulatory filings on US executive and director changes from June 22, 2026. A dominant theme is significant leadership transitions at the CEO and CFO level across diverse sectors, including Domino's Pizza, NVE Corp, Johnson Outdoors, TaskUs, and PagerDuty. Several large-cap companies, such as A. O. Smith and Best Buy, are executing multi-year succession plans that underscore a focus on internal talent development. A high-conviction insider acquisition at IMA Tech saw a change of control, while notable shareholder dissent at MARA Holdings (40.8% withheld vote) and Oric Pharmaceuticals signals governance concerns. Mixed earnings guidance from Primoris Services Corp (adjusted EBITDA cut ~37%) is a major risk flag, while the overall tone of board appointments remains neutral to positive, with a notable addition of financial and operational expertise from companies like Centene and TD SYNNEX.

50 high priority 50 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — June 22, 2026

Today's filings reveal a significant uptick in distress signals across micro-cap companies, with going concern risks, repeated defaults, and emergency equity offerings dominating the landscape. We see four companies in active liquidity crises (Algorhythm Holdings, Sable Offshore, Exyn Technologies) or warning of going concern uncertainty (CervoMed), while several others are forced to issue highly dilutive convertible notes or sell stock at deep discounts. A sharp bifurcation is evident: large-cap M&A (CRH/Arcosa, AbbVie/Apogee, Booz Allen) provides a bright spot, but for smaller firms, cash preservation through debt renegotiation, asset subleasing, and insider-funded advances is the prevailing theme. The average sentiment across all filings is neutral-to-mixed, with no sector-wide positive trends emerging in period-over-period comparisons as most filings lacked quantitative revenue or margin data. Key actionable insights include betting on the acquirers (CRH, AbbVie) and avoiding the most distressed micro-caps.

41 high priority 41 total filings
· daily

US Corporate Board Director Changes SEC Filings — June 22, 2026

Today's digest of 50 USA board room changes reveals a significant uptick in CEO and C-suite successions, with a clear focus on internal promotions alongside a few notable departures linked to operational performance. The period-over-period data highlights divergent strategic outcomes: while companies like Domino's Pizza and PagerDuty leverage strong operational momentum for leadership transitions, Primoris Services exemplifies a direct link between board-level changes and severe financial underperformance, slashing its 2026 guidance by nearly 70%. A key theme is the increasing use of shareholder meetings as a barometer of investor sentiment, with director elections at ORIC Pharmaceuticals, MARA Holdings, and BridgeBio Oncology Therapeutics revealing notable opposition (19-41% withheld votes), signaling governance concerns or strategic disagreements. Insider activity is muted in the filings, but capital allocation moves, such as Primoris's $50M buyback and Domino's significant retail sales growth, provide context for new management's mandate. The synthesis underscores that while many changes are routine successions, several carry high materiality due to their linkage to strategic pivots, severe guidance revisions, or shareholder revolts.

50 high priority 50 total filings
· daily

USA Insider Trading Pulse — June 22, 2026

The June 22, 2026 insider trading pulse reveals a bifurcated market: heavy insider liquidation at firms like uniQure (CEO sold $2.47M under a 10b5-1 plan) and Belite Bio (CMO sold $707K), contrasting with strong insider conviction at beaten-down Chinese ADRs (Gaotu Techedu CEO bought $418K, Baozun executives bought ~$80K combined) and select value plays (Mission Produce director bought $3.23M). Director stock option grants at Omeros and restricted stock unit awards across Yum China's management team signal long-term alignment but no immediate market-moving conviction. Period-over-period comparisons from enriched data show no revenue/margin trends as filings are all Form 4s, but the pattern of Chinese management buying into weakness warrants attention as a potential contrarian signal. The most actionable themes are the Chinese education/e-commerce insider buying cluster, the high-conviction director purchase at Mission Produce, and the risk flags from the uniQure CEO sell-down and VinFast's massive preference share disposal.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — June 22, 2026

The USA M&A landscape on June 22, 2026, is dominated by SPAC activity and strategic divestitures. Two SPACs (Live Oak Acquisition Corp. V and Real Asset Acquisition Corp.) are progressing toward business combinations, with Live Oak facing a massive 80% shareholder redemption, signaling market skepticism. Kosmos Energy completed a divestiture of Equatorial Guinea assets, improving its balance sheet but reducing revenue. P10 (Ridgepost Capital) closed an acquisition of Stellus Capital Management, expanding its private credit platform. YHN Acquisition I extended its deadline, highlighting SPAC time pressure. Quantum Leap Acquisition Corp. and Safe & Green Holdings Corp. are in earlier stages. Key trends include high SPAC redemptions, strategic divestitures for debt reduction, and consolidation in asset management. No insider trading or forward guidance was reported in these filings.

7 high priority 7 total filings
· monthly

US Pre-Market SEC Filings Roundup — June 22, 2026

The overnight filing cycle reveals a market focused on corporate governance resets, M&A regulatory progress, and energy transition investments. Mixed earnings seasonality is evident with widening losses at Atlantic International and Pemex contrasting with a dramatic GAAP net income swing at America Great Health. A significant cluster of SPAC and de-SPAC activity (Graf Global/BIG3, RYVYL/RTB Digital) points to aggressive consolidation in thematic sectors. Notable insider and board moves include Ryanair's long-term CEO extension with ambitious performance hurdles and a leadership change at Panamera Holdings to drive a key combination. Regulatory milestones for major deals (Baker Hughes/Chart Industries, Paramount Skydance/WBD) are advancing, while litigation and audit risks at Bioceres and Webstar Technology present specific pitfalls. Capital allocation is mixed, with News Corp maintaining a $1B buyback and First United declaring a dividend, while CervoMed's dilutive $10M offering highlights the ongoing cash needs for pre-revenue biotechs.

21 high priority 29 medium 50 total filings
· daily

Defense Manufacturing Contracts — June 21, 2026

The single contract analyzed, a $1.26B award from the Department of Homeland Security (DHS) to Bollinger Shipyards Lockport, L.L.C., dominates the period and represents a significant civilian-agency defense procurement. This is a high-conviction, high-materiality signal for Bollinger, though the lack of pricing details and competition data introduces execution risk. The award underscores DHS's reliance on specialized shipyards for maritime security assets, a theme that benefits niche defense industrial base players. Key watch items include the contract's pricing structure (fixed-price vs. cost-plus) and whether this is a sole-source or competed award, which would materially alter the competitive moat assessment.

1 total filings
· daily

DHS Homeland Security Contracts — June 21, 2026

This single-day digest captures a single, highly material $1.26B Department of Homeland Security (DHS) contract awarded to Bollinger Shipyards Lockport, L.L.C. on December 19, 2025. Despite being classified under DHS, the contract is explicitly labeled as a defense contract, suggesting it supports a DHS mission with national security or military-adjacent applications, such as U.S. Coast Guard vessel construction. The award is 100% civilian-agency (DHS) with zero defense-related contracts in the period, but the $1.26B value and 7/10 signal strength make it the highest-conviction signal. Key risks include the lack of disclosed pricing structure (fixed-price vs. cost-plus) and competition details, which limit full risk assessment. Bollinger Shipyards is the sole beneficiary, creating a significant concentration risk for investors tracking DHS or defense shipbuilding exposure.

1 total filings
· daily

HHS & Healthcare Contracts Intelligence — June 21, 2026

This digest covers a single, massive $1.78B contract awarded to Leidos Biomedical Research Inc. by the Department of Health and Human Services (HHS), representing a purely civilian healthcare sector award with no defense exposure. The contract is a high-conviction bullish signal for Leidos, given its size relative to typical biomedical research awards, though the lack of pricing and competition details introduces execution and budget risk. The dominant theme is HHS's continued reliance on Leidos for large-scale biomedical research support, likely tied to the National Institutes of Health (NIH) mission. Key watch items include the contract's fixed-price vs. cost-plus structure and potential vulnerability to HHS budget reallocations or continuing resolution (CR) impacts in future fiscal years.

1 total filings
· daily

New Federal Contractors — June 21, 2026

Over a single day, June 21, 2026, two massive civilian-agency contracts totaling $3.04B were awarded, with zero defense-related obligations. The dominant theme is dual-use infrastructure: a $1.78B HHS contract to Leidos Biomedical Research for health/biodefense work, and a $1.26B DHS contract to Bollinger Shipyards for homeland security vessel construction. The highest-conviction signal is the sheer size and sole-source-like nature of both awards, suggesting deep incumbency or urgent mission need. A key risk is the lack of competition data—both awards may be sole-source or limited-competition, raising protest vulnerability and pricing opacity for investors.

2 total filings
· daily

Significant Contract Modifications ($10M+) — June 21, 2026

The two contracts analyzed, totaling $3.04 billion, are both classified as defense-related despite being awarded by civilian agencies—the Department of Health and Human Services (HHS) and the Department of Homeland Security (DHS)—highlighting a critical blurring of lines between civilian and defense spending. The dominant signal is a $1.78B award to Leidos Biomedical Research Inc. from HHS, representing the highest-conviction opportunity in the digest, while Bollinger Shipyards Lockport's $1.26B DHS contract underscores a separate maritime security theme. Both contracts carry bullish signals with a strong average signal strength of 7.0/10, but the absence of competitive or pricing data introduces execution and budget risks. Key watch items include potential continuing resolution (CR) impacts on HHS funding and DHS budget reauthorization timelines.

2 total filings
· daily

Contract Deobligations Alert — June 21, 2026

Over a single day on June 21, 2026, the government awarded $3.04B in total obligations, split entirely across civilian agencies (0% defense-related). The dominant theme is a massive $1.78B deobligation to Leidos Biomedical Research from HHS, paired with a $1.26B award to Bollinger Shipyards Lockport from DHS. Despite being labeled 'defense contracts' in the stream, both are civilian—Leidos supports biomedical research (likely NIH/NCI) and Bollinger builds Coast Guard vessels. The highest-conviction signal is the Leidos Biomedical award, which represents a material 58% of the aggregate and suggests sustained federal investment in health research infrastructure. A key risk is that both are deobligations (not new money), potentially indicating budget reallocations or contract closeouts rather than fresh spending, which could signal tightening civilian agency budgets.

2 total filings
· daily

Contract Option Exercises — June 21, 2026

The digest covers $3.04 billion in contract option exercises from June 21, 2026, split between two large awards, both classified as non-defense despite the agencies involved. The dominant theme is civilian agency spending, with the Department of Health and Human Services (HHS) accounting for $1.78 billion to Leidos Biomedical Research Inc. and the Department of Homeland Security (DHS) awarding $1.26 billion to Bollinger Shipyards Lockport, L.L.C. The highest-conviction signal is the sheer scale of the Leidos award, which represents a major biomedical research commitment. A key risk is the lack of pricing and competition details for both contracts, which obscures margin and protest risk.

2 total filings
· daily

All HHS Contracts — June 21, 2026

A single, massive $1.78B contract from the Department of Health and Human Services (HHS) to Leidos Biomedical Research Inc. dominates the period, representing 100% of the total obligation. This is a civilian agency award, not defense-related, and carries a bullish signal with high materiality (8/10). The contract's size suggests a critical, likely sole-source or follow-on award for biomedical research support, potentially tied to the National Cancer Institute or similar HHS entity. Key risks include execution risk given the large fixed-price or cost-plus nature (unknown pricing) and concentration risk for Leidos if this represents a significant portion of its revenue. Investors should watch for contract details (pricing type, competition status) and Leidos' upcoming earnings disclosures for revenue recognition guidance.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — June 21, 2026

Over a single-day period, two mega-contracts totaling $3.04B were awarded, both classified as defense-related but originating from civilian agencies (HHS and DHS), highlighting a critical trend of non-DoD agencies driving defense-adjacent spending. Leidos Biomedical Research Inc. secured the largest award at $1.78B from HHS, signaling sustained biodefense and health security priorities. Bollinger Shipyards Lockport won a $1.26B DHS contract, reinforcing homeland maritime security investments. Both signals are bullish with high materiality, but the lack of competitive or pricing data introduces execution and budget risk, especially under potential Continuing Resolution constraints. The dominant theme is civilian-agency defense spending, with Leidos and Bollinger as the highest-conviction beneficiaries.

2 total filings
· daily

High-Value Federal Grants ($5M+) — June 21, 2026

The digest covers $3.04 billion in high-value federal obligations from June 21, 2026, split between two civilian-agency contracts with no defense-related awards. The dominant theme is large-scale, single-award contracts to niche contractors: Leidos Biomedical Research Inc. secured a $1.78B award from HHS, while Bollinger Shipyards Lockport won a $1.26B award from DHS. Both contracts carry bullish signals with high materiality, but the lack of competition data and unknown pricing structures introduce execution and budget risk. The highest-conviction signal is the sheer size of the Leidos Biomedical award, which suggests deep incumbency in health research support, though the absence of defense exposure limits sector-wide defense upside. Key watch items include potential protest risk on the Bollinger shipbuilding award and the impact of continuing resolutions on HHS funding for Leidos Biomedical.

2 total filings
· daily

General Federal Contracts — June 21, 2026

The two contracts analyzed total $3.04 billion, both classified as civilian awards despite being labeled 'defense' in the raw data. The Department of Health and Human Services (HHS) dominates with a $1.78B award to Leidos Biomedical Research Inc., while the Department of Homeland Security (DHS) contributes $1.26B to Bollinger Shipyards Lockport, L.L.C. The highest-conviction signal is the Leidos Biomedical award, which represents a massive, single-source obligation that could indicate a long-term operational contract. A key risk is the lack of pricing and competition data for both awards, which obscures margin and protest risk. The digest highlights a civilian agency spending surge but notes the absence of pure defense contracts, which may signal a shift in federal procurement focus away from DOD in this period.

2 total filings
· daily

Federal Construction & Infrastructure Contracts — June 20, 2026

This digest covers a single $126.8M civilian infrastructure contract awarded by the General Services Administration (GSA) to Ryan Companies US Inc for a new federal courthouse in Des Moines, IA. The contract is entirely civilian, with no defense exposure, and reflects stable GSA investment in federal building modernization. The fixed-price incentive pricing introduces moderate execution risk, though $84.4M has already been outlayed, reducing future funding uncertainty. The neutral signal strength (6/10) and full-and-open competition suggest a competitive win without a clear moat. Key watch items include margin performance on the incentive structure and potential option exercises for scope expansion.

1 total filings
· daily

New Federal Contractors — June 20, 2026

This digest covers four contracts totaling $550.5 million, all awarded by civilian agencies (0% defense-related), with no single contractor receiving multiple awards. The dominant theme is stable, long-duration civilian IT and professional services: Booz Allen Hamilton ($142.9M) and Accenture Federal Services ($141.7M) both secured large CMS and State Department contracts, respectively, providing multi-year revenue visibility. The highest-conviction signal is Booz Allen’s firm-fixed-price CMS win, which represents a durable, competitive win in a stable federal program evaluation market. Key risks include cost-plus pricing suppressing margins at Accenture and potential budget uncertainty for NASA science programs following the PUNCH contract’s upcoming expiry in 2027. With an average signal strength of 5.8/10, this batch offers modest investment insight, weighted toward civilian IT services stability rather than transformative defense growth.

4 total filings